With its liquid biopsy approval, Foundation Medicine takes on Guardant
The first pan-cancer approval might have gone to Guardant, but Roche’s subsidiary’s blood test appears to be able to find more markers.
Does FDA’s plasma nod set a dangerous precedent?
The FDA’s emergency use authorisation for plasma for Covid-19 looks questionable. If this presages an early vaccine nod, we should be very afraid.
